Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results


2009 | 4 | 3 | 327-330

Article title

Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin


Title variants

Languages of publication



The aim of the study was to investigate the role of cTnT for the prediction of long term cardiac dysfunction after epirubicin-containing adjuvant chemotherapy for breast cancer. The study group comprised of 45 patients (all female; mean age 48 ±8 years), treated with epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer. Patients received either 4 cycles of cyclophosphamide plus epirubicin (90 mg/m2) (n=23; stage 2 breast cancer) or 6 cycles of cyclophosphamide plus epirubicin (75 mg/m2) plus fluorouracil (n=18; stage 3 breast cancer). Venous blood samples were drawn, before and 72 hours after, every cycle of chemotherapy for the measurement of cTnT. Cardiac assessment was carried out at baseline and 1 year after chemotherapy by clinical evaluation, electrocardiography, radio-nuclide ventriculography (RNV) and transthoracic echocardiography. All patients remained free of clinical heart failure during the study period. In 26 patients (63%), cTnT was elevated after chemotherapy. Mean left ventricular ejection fraction, assessed by RNV at baseline and one year after chemotherapy, were 61±8% and 56±7% (p<0.0001). The sensitivity and specifity of cTnT for the detection of left ventricular systolic dysfunction at one year were 69% and 39% respectively. Echocardiographic examinations at baseline and one year after chemotherapy revealed a significant decrease in E/A ratio from 1.15±0.3 to 0.9±0.2 in cTnT positive patients, suggesting diastolic dysfunction. In conclusion, elevated serum cTnT levels after epirubicin-containing adjuvant chemotherapy for stage 2 and stage 3 breast cancer, predict future cardiac dysfunction with moderate sensitivity and poor specificity.










Physical description


1 - 9 - 2009
3 - 7 - 2009


  • Florence Nightingale Hospital, 34119, Istanbul, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey
  • Namik Kemal University Hospital, 59030, Tekirdag, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey
  • Marmara University Hospital, 34633, Istanbul, Turkey


  • [1] Shan K., Lincoff A.M., Young J.B., Anthracycline-induced cardiotoxicity, Ann. Intern. Med., 1996, 125, 47–58
  • [2] Lipshultz S.E., Colan S.D., Gelber R.D., Perez-Atayde A.R., Sallan S.E., Sanders S.P., Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood, N. Engl. J. Med., 1991, 324, 808–15
  • [3] Scully R.E., Lipshultz S.E., Anthracycline cardiotoxicity in long-term survivors of childhood cancer, Cardiovasc. Toxicol., 2007, 7, 122–8 http://dx.doi.org/10.1007/s12012-007-0006-4[Crossref][WoS]
  • [4] Thomas X., Le Q.H., Fiere D., Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia, Ann. Hematol., 2002, 81, 504–7 http://dx.doi.org/10.1007/s00277-002-0534-8[Crossref]
  • [5] Gaze D.C., Collinson P.O., Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection, Expert Opin. Drug. Metab. Toxicol., 2005, 1, 715–25 http://dx.doi.org/10.1517/17425255.1.4.715[Crossref]
  • [6] Cardinale D., Sandri M.T., Colombo A., Colombo N., Boeri M., Lamantia G., et al., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation, 2004, 109, 2749–54 http://dx.doi.org/10.1161/01.CIR.0000130926.51766.CC[Crossref]
  • [7] Kilickap S., Barista I., Akgul E., Aytemir K., Aksoyek S., Aksoy S., et al., cTnT can be a useful marker for early detection of anthracycline cardiotoxicity, Ann. Oncol., 2005, 16, 798–804 http://dx.doi.org/10.1093/annonc/mdi152[Crossref]
  • [8] Arcamone F., Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture., Cancer Res., 1985, 45, 5995–9
  • [9] Glück S., Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin, Oncologist, 2005, 10, 780–91 http://dx.doi.org/10.1634/theoncologist.10-10-780[Crossref]
  • [10] Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials, Lancet, 1998, 352, 930–942 http://dx.doi.org/10.1016/S0140-6736(98)03301-7[Crossref]
  • [11] Levine M.N., Whelan T., Adjuvant chemotherapy for breast cancer-30 years later, N. Engl. J. Med., 2006, 355, 1920–2 http://dx.doi.org/10.1056/NEJMe068204
  • [12] Meinardi M.T., van der Graaf W.T., van Veldhuisen D.J., Gietema J.A., de Vries E.G., Sleijfer D.T., Detection of anthracycline-induced cardiotoxicity, Cancer Treat. Rev., 1999, 25, 237–47 http://dx.doi.org/10.1053/ctrv.1999.0128[Crossref]
  • [13] Jannazzo A., Hoffman J., Lutz M., Monitoring of anthracycline-induced cardiotoxicity, Ann. Pharmacother., 2008, 42, 99–104 [WoS]
  • [14] Jones R.L., Miles D.W., Use of endomyocardial biopsy to assess anthracycline-induced cardiotoxicity, Lancet Oncol., 2005, 6, 67 http://dx.doi.org/10.1016/S1470-2045(05)01719-5[Crossref]
  • [15] Vogelsang T.W., Jensen R.J., Hesse B., Kjaer A., BNP cannot replace gated equilibrium radionuclide ventriculography in monitoring of anthracycline-induced cardiotoxity, Int. J. Cardiol., 2008, 124, 193–7 http://dx.doi.org/10.1016/j.ijcard.2007.02.003[Crossref][WoS]
  • [16] Cheitlin M.D., Armstrong W.F., Aurigemma G.P., Beller G.A., Bierman F.Z., Davis J.L., et al.,; ACC; AHA; ASE. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography), J. Am. Soc. Echocardiogr., 2003, 16, 1091–110
  • [17] Bu’Lock F.A., Mott M.G., Oakhill A., Martin R.P., Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology, Br. Heart J., 1995, 73, 340–50 http://dx.doi.org/10.1136/hrt.73.4.340[Crossref]
  • [18] Dorup I., Levitt G., Sullivan I., Sorensen K., Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: the role of diastolic function, Heart, 2004, 90, 1214–6 http://dx.doi.org/10.1136/hrt.2003.027516[Crossref]
  • [19] Erkus B., Demirtas S., Yarpuzlu A.A., Can M., Genc Y., Karaca L., Early prediction of anthracycline induced cardiotoxicity, Acta Paediatr., 2007, 96, 506–9 http://dx.doi.org/10.1111/j.1651-2227.2006.00174.x[WoS][Crossref]
  • [20] Specchia G., Buquicchio C., Pansini N., Di Serio F., Liso V., Pastore D., et al., Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J. Lab. Clin. Med., 2005, 145, 212–20 http://dx.doi.org/10.1016/j.lab.2005.02.003[Crossref]
  • [21] Nisticò C., Bria E., Cuppone F., Carpino A., Ferretti G., Vitelli G., et al., Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients, Anticancer Drugs., 2007, 18, 227–32 http://dx.doi.org/10.1097/CAD.0b013e328011335e[Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.